The Plk1 inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitro.

BI 2536 is a new anti-mitotic drug that targets polo-like kinase 1 (Plk1) and is currently under clinical development for cancer therapy. The effect of this drug on cancer cells has been extensively investigated, but information about the effects on primary dividing cells and differentiated non-divi...

Full description

Bibliographic Details
Main Authors: Bo Lu, Hasan Mahmud, Alexander H Maass, Bo Yu, Wiek H van Gilst, Rudolf A de Boer, Herman H W Silljé
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2945759?pdf=render

Similar Items